Success Metrics

Clinical Success Rate
87.1%

Based on 88 completed trials

Completion Rate
87%(88/101)
Active Trials
2(2%)
Results Posted
28%(25 trials)
Terminated
13(12%)

Phase Distribution

Ph phase_2
21
19%
Ph phase_3
9
8%
Ph early_phase_1
4
4%
Ph phase_4
2
2%
Ph phase_1
69
62%
Ph not_applicable
5
5%

Phase Distribution

73

Early Stage

21

Mid Stage

11

Late Stage

Phase Distribution110 total trials
Early Phase 1First-in-human
4(3.6%)
Phase 1Safety & dosage
69(62.7%)
Phase 2Efficacy & side effects
21(19.1%)
Phase 3Large-scale testing
9(8.2%)
Phase 4Post-market surveillance
2(1.8%)
N/ANon-phased studies
5(4.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.8%

88 of 105 finished

Non-Completion Rate

16.2%

17 ended early

Currently Active

2

trials recruiting

Total Trials

111

all time

Status Distribution
Active(2)
Completed(88)
Terminated(17)
Other(4)

Detailed Status

Completed88
Terminated13
Withdrawn4
unknown4
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
111
Active
2
Success Rate
87.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (3.6%)
Phase 169 (62.7%)
Phase 221 (19.1%)
Phase 39 (8.2%)
Phase 42 (1.8%)
N/A5 (4.5%)

Trials by Status

withdrawn44%
recruiting11%
active_not_recruiting11%
terminated1312%
completed8879%
unknown44%

Recent Activity

2 active trials
Showing 5 of 111
completedphase_1

N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

NCT00295919
active_not_recruitingphase_2

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

NCT00859781
terminatedearly_phase_1

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases

NCT03796273
terminatedearly_phase_1

Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas

NCT04869449
completedearly_phase_1

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

NCT03471364
View all 111 trials

Clinical Trials (111)

Showing 20 of 111 trialsScroll for more
NCT00295919Phase 1

N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

Completed
NCT00859781Phase 2

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Active Not Recruiting
NCT03796273Early Phase 1

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases

Terminated
NCT04869449Early Phase 1

Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas

Terminated
NCT03471364Early Phase 1

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

Completed
NCT02256865Early Phase 1

Hormonal Mechanisms of Sleep Restriction

Completed
NCT06560086Not Applicable

Ketoconazole Contributes to Cryptorchidism Outcome Via Modulating Macrophage Trem2

Recruiting
NCT00019695Phase 2

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

Terminated
NCT01154764Phase 1

Trial for Studying Pharmacokinetic Effects of Ketoconazole on CG100649

Completed
NCT00027859Phase 3

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

Completed
NCT02163356Phase 1

Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma

Terminated
NCT02075177

Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma

Unknown
NCT00030654Phase 3

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Completed
NCT03320486Phase 3

Non-inferiority Trial of Dapaconazole Versus Ketoconazole

Completed
NCT00460031Phase 2

Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Completed
NCT01036594Phase 2

Ketoconazole and Dexamethasone in Prostate Cancer

Completed
NCT04212000Phase 1

Bioavailability of Levoketoconazole and Ketoconazole Tablets

Completed
NCT02147964Phase 2

ITT-5 Mechanisms of Spermatogenesis in Man

Withdrawn
NCT00675714Phase 2

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

Terminated
NCT01324310Phase 1

Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Completed

Drug Details

Intervention Type
DRUG
Total Trials
111